raloksyfen
Raloksyfen is not a widely recognized chemical name in major pharmacological references. It may be a misspelling or variant spelling of raloxifene, a selective estrogen receptor modulator (SERM) used in osteoporosis and breast cancer risk reduction.
Raloxifene is approved for the prevention and treatment of osteoporosis in postmenopausal women and to reduce
Mechanism: Raloxifene binds to estrogen receptors in bone, acting as an agonist to help maintain bone density,
Administration: The usual dose is 60 mg taken once daily by mouth. It is metabolized in the
Safety: Common side effects include hot flashes and leg cramps. Serious risks include venous thromboembolism and,
History and availability: Raloxifene was developed by pharmaceutical companies and marketed under the brand name Evista.